Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › MA › Marlborough › NPI 1396738159
Clinic

Marlborough Hospital Corp

Marlborough Hospital Corp was paid $26.78M by Medicaid between Jan 2018 and Dec 2024, across 208 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 17% of everything it billed.

33Billing provider infoMARLBOROUGH HOSPITAL CORP
MARLBOROUGH, MA 01752
33aNPI1396738159assigned 08/26/2005
33bProvider typeCommunity Health Clinic/Center
28Total paid$26.78M
24GClaims630,914
24DCodes billed208
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Community Health Clinic/Center providers in Massachusetts

Rank by total paid#9 of 36
Median peer was paid$3.62M
This provider vs. median7.4×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K$600K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201867,581$3.20M
201974,259$2.96M
202073,742$2.82M
2021109,893$3.83M
2022108,542$4.51M
2023106,884$5.10M
2024incomplete90,013$4.36M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
96361 Intravenous infusion, hydration; each additional hour 17% 13,002 11,336 $4.67M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 17% 25,372 22,843 $4.51M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 13% 23,068 21,560 $3.40M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 12% 20,930 19,301 $3.14M
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 6.2% 31,357 9,662 $1.67M
74177 Computed tomography, abdomen and pelvis; with contrast material 3.5% 6,049 5,745 $935K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 3.2% 7,488 7,088 $868K
S9485 Crisis intervention mental health services, per diem 2.7% 1,490 889 $728K
99282 Emergency department visit for the evaluation and management, low to moderate severity 2.7% 5,131 4,938 $721K
70450 Computed tomography, head or brain; without contrast material 1.9% 4,643 4,260 $500K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour 1.5% 3,726 3,472 $408K
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 1.5% 6,411 5,824 $389K
196 more codes
G0378 Hospital observation service, per hour 1.3% 3,686 $346K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 1.1% 2,838 $307K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) 1.1% 15,747 $288K
97161 <1% 4,589 $261K
77063 Screening digital breast tomosynthesis, bilateral <1% 3,863 $243K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 4,838 $231K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 1,599 $216K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 39,144 $175K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 1,115 $147K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 1,511 $141K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 8,339 $136K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 1,401 $127K
71046 Radiologic examination, chest; 2 views <1% 11,388 $110K
93975 <1% 933 $96K
84484 <1% 14,567 $90K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 1,317 $70K
99291 Critical care, evaluation and management of the critically ill patient, first 30-74 minutes <1% 465 $70K
ATP14 <1% 7,521 $66K
ATP08 <1% 9,010 $64K
77067 Screening mammography, bilateral, including computer-aided detection <1% 3,879 $62K
0001A <1% 2,323 $61K
0002A <1% 2,186 $58K
70496 <1% 432 $55K
80048 Basic metabolic panel (calcium, ionized) <1% 24,338 $52K
76830 Ultrasound, transvaginal <1% 861 $50K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 3,074 $49K
80053 Comprehensive metabolic panel <1% 18,444 $49K
81025 <1% 7,093 $48K
83690 <1% 9,614 $47K
83735 <1% 11,178 $43K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 13,200 $42K
93971 <1% 252 $41K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 1,165 $40K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 3,083 $38K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 1,371 $35K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 1,370 $35K
76770 <1% 213 $32K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 495 $31K
87086 Culture, bacterial; quantitative colony count, urine <1% 5,722 $31K
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination <1% 1,626 $26K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 903 $26K
84443 Thyroid stimulating hormone (TSH) <1% 3,242 $24K
84703 <1% 4,164 $24K
76642 <1% 400 $23K
81001 <1% 10,253 $23K
87631 <1% 201 $21K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 17,045 $18K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 2,997 $18K
ATP15 <1% 2,418 $17K
83605 <1% 2,652 $16K
J1650 Injection, enoxaparin sodium, 10 mg <1% 2,079 $16K
36415 Collection of venous blood by venipuncture <1% 43,983 $16K
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple <1% 27 $16K
71045 Radiologic examination, chest; single view <1% 4,394 $15K
87088 <1% 2,642 $15K
96375 Therapeutic injection; each additional sequential IV push <1% 8,069 $15K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 1,093 $15K
0012A <1% 580 $14K
87081 <1% 2,531 $14K
83880 <1% 871 $13K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 214 $13K
87040 <1% 2,203 $13K
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 2,934 $12K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 968 $12K
93017 <1% 155 $12K
83036 Hemoglobin; glycosylated (A1C) <1% 2,753 $12K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 1,157 $11K
0011A <1% 532 $11K
82962 <1% 7,927 $11K
85027 <1% 3,501 $10K
84702 <1% 855 $10K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 9,408 $10K
81003 <1% 6,234 $10K
85379 <1% 1,377 $10K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 9,332 $9K
73630 <1% 1,281 $9K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 85 $9K
72125 Computed tomography, cervical spine; without contrast material <1% 1,422 $8K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 90 $8K
70498 <1% 423 $8K
85610 <1% 3,849 $8K
J1790 Injection, droperidol, up to 5 mg <1% 430 $7K
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 375 $6K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 9,449 $6K
80061 Lipid panel <1% 3,300 $6K
73130 <1% 608 $5K
97162 <1% 80 $5K
78452 Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress <1% 13 $5K
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 1,666 $5K
73030 <1% 602 $5K
87077 <1% 955 $5K
72100 <1% 313 $5K
71250 <1% 186 $4K
87186 <1% 740 $4K
73610 <1% 983 $4K
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 1,575 $4K
J2060 Injection, lorazepam, 2 mg <1% 1,015 $4K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 15 $4K
J2270 Injection, morphine sulfate, up to 10 mg <1% 4,042 $4K
86850 <1% 651 $4K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 2,737 $4K
80050 General health panel <1% 192 $3K
87210 <1% 461 $3K
86803 <1% 435 $3K
76641 <1% 45 $3K
12001 <1% 12 $3K
73110 <1% 293 $3K
97014 <1% 55 $2K
82607 <1% 405 $2K
45385 Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) <1% 13 $2K
76882 <1% 13 $2K
96376 <1% 740 $2K
82803 <1% 161 $2K
76536 <1% 25 $2K
77080 <1% 56 $2K
82728 <1% 283 $2K
77065 Tomosynthesis, mammo <1% 49 $2K
86140 <1% 691 $2K
J2704 Injection, propofol, 10 mg <1% 2,923 $2K
A9270 Non-covered item or service <1% 2,781 $2K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 724 $2K
80076 <1% 2,905 $2K
90714 <1% 81 $1K
86901 <1% 786 $1K
86900 <1% 774 $1K
73562 <1% 680 $1K
76870 <1% 12 $1K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 2,115 $1K
77066 Tomosynthesis, mammo <1% 56 $1K
85652 <1% 786 $1K
84439 <1% 257 $972.91
0031A <1% 50 $963.27
ATP17 <1% 199 $895.62
82570 <1% 485 $888.02
71271 <1% 28 $849.88
83540 <1% 280 $836.39
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 1,224 $797.07
90686 <1% 74 $766.87
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 591 $674.80
83550 <1% 167 $668.71
77062 <1% 13 $651.48
82077 <1% 632 $618.01
ATP03 <1% 135 $498.40
73502 <1% 102 $441.04
84153 <1% 80 $400.86
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 1,362 $399.50
82746 <1% 58 $394.38
97535 Self-care/home management training, each 15 minutes <1% 12 $341.38
80179 <1% 68 $319.60
J7050 Infusion, normal saline solution, 250 cc <1% 2,289 $302.57
J0690 Injection, cefazolin sodium, 500 mg <1% 308 $302.40
85730 <1% 101 $263.60
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 864 $261.67
84100 <1% 2,198 $248.41
97116 <1% 19 $236.33
J3475 Injection, magnesium sulfate, per 500 mg <1% 312 $227.32
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 12 $212.40
80143 <1% 71 $172.70
87070 <1% 24 $121.68
82043 <1% 70 $119.18
J1644 Injection, heparin sodium, per 1000 units <1% 22 $94.60
86618 <1% 12 $93.18
90791 Psychiatric diagnostic evaluation <1% 25 $82.04
74019 <1% 15 $75.61
ATP11 <1% 12 $73.92
77091 <1% 29 $67.68
ATP10 <1% 12 $54.54
87205 <1% 12 $35.20
J1170 Injection, hydromorphone, up to 4 mg <1% 153 $32.47
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 1,467 $27.64
82550 <1% 127 $11.88
76376 0% 371 $0.00
73590 0% 12 $0.00
J7120 Ringers lactate infusion, up to 1000 cc 0% 832 $0.00
J7030 Infusion, normal saline solution , 1000 cc 0% 236 $0.00
82248 0% 12 $0.00
J0689 Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg 0% 41 $0.00
G8979 Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 0% 94 $0.00
91300 0% 4,046 $0.00
G8978 Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals 0% 62 $0.00
84460 0% 41 $0.00
J8499 Prescription drug, oral, non chemotherapeutic, nos 0% 108 $0.00
84450 0% 28 $0.00
73080 0% 13 $0.00
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg 0% 19 $0.00
S0164 Injection, pantoprazole sodium, 40 mg 0% 18 $0.00
80069 0% 39 $0.00
91301 0% 763 $0.00
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal 0% 16 $0.00
94761 0% 85 $0.00
76801 0% 16 $0.00
91303 0% 45 $0.00
88304 0% 14 $0.00
J0330 Injection, succinylcholine chloride, up to 20 mg 0% 14 $0.00
J1815 Injection, insulin, per 5 units 0% 15 $0.00
A9500 Technetium tc-99m sestamibi, diagnostic, per study dose 0% 15 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMCCUE, STEVEN (CFO)